At a glance
- Note: These files are not yet fully accessible for all audiences.
- Slides and other meeting materials will be added as they become available.
June 25, 2025
Opening Remarks
Dr. Martin Kulldorff
Welcome and Roll Call
Introduction
Dr. Mina Zadeh
Update on Work Groups
Dr. M Kulldorff
COVID-19 Vaccines
Dr. A MacNeil
Dr. A MacNeil
COVID-19 vaccine effectiveness update
Dr. A MacNeil
Dr. S Meyer
COVID-19 vaccine coverage and implementation
Dr. G Peacock
Evidence to recommendations (partial)
Dr. A MacNeil
Agency Updates
CDC, CMS, FDA, HRSA, IHS, NIH
RSV Vaccines- Maternal/Pediatric
Dr. A MacNeil
Updates on uptake of maternal vaccine and nirsevimab
Dr. G Peacock
Effectiveness and impact of RSV prevention products in infants during the 2024-2025 season
Dr. A MacNeil
Updates on safety of maternal vaccine and nirsevimab
part 1, Dr. M DeSilva
part 2, Dr. M Daley
Updates and summary of the Evidence to Recommendation Framework for clesrovimab
Dr. A MacNeil
Updates on clinical considerations for clesrovimab
Dr. A MacNeil
Proposed Recommendations
Dr. A MacNeil
Updates to RSV vaccines VFC resolution
Dr. G Peacock
June 26, 2025
Welcome and Roll Call
Dr. Mina Zadeh
Influenza Vaccines
Dr. V Dugan
Flublok in older children and adolescents: immunogenicity and safety
Dr. P Folegatti
Estimates of influenza burden and burden averted through vaccination
Dr. V Dugan
Proposed recommendations for 2025-26
Dr. V Dugan
Presentation regarding thimerosal in vaccines
L Redwood, RN, MSN
Proposed recommendations regarding thimerosal containing influenza vaccine
Dr. M Kulldorff
Chikungunya Vaccines
Introduction
Dr. L Petersen
Dr. L Petersen
Safety update on live attenuated chikungunya vaccine and use among older persons
Dr. L Petersen
Anthrax Vaccine
Dr. B Jackson
MMRV Vaccine
*CDC background briefing material* MMRV Vaccine Safety
Presentation on MMRV vaccine in children under under 5 years of age
Dr. M Kulldorff
Proposed recommendations regarding MMRV in children under 5 years of age
Dr. M Kulldorff